Benzinga | Nov 5, 2020 07:07AM EST

Biocryst Pharmaceuticals Q3 EPS $(0.26) Misses $(0.25) Estimate, Sales $6.10M Beat $3.60M Estimate

Biocryst Pharmaceuticals (NASDAQ:BCRX) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.25) by 4 percent. This is a 23.53 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $6.10 million which beat the analyst consensus estimate of $3.60 million by 69.50 percent. This is a 243.77 percent increase over sales of $1.77 million the same period last year.